KEY EVENTS /// Transformative times for Pharma Mar; catalyst rich 2017 :
* Yondelis® approved in Japan for STS (9/2015); approved in the US for STS (10/2015) .
* Lurbinectedin Phase III pivotal trial initiated for SCLC (Aug. 2016) .
* Lurbinectedin interim activity analysis Phase III in platinum-resistant ovarian cancer (Aug`16) .
* Aplidin® positive data for Phase III for multiple myeloma and dossier submitted (Sept. 2016) .
* Lurbinectedin data for Phase II metastatic breast cancer (Sept. 2016) .
* Lurbinectedin Phase III in platinum-resistant ovarian cancer: recruitment completed (Oct`16) .
* Lurbinectedin license agreement in Japan (Chugai, Dec´16) .
* Update Breast cancer trial, following FDA meeting .
* Yondelis INNOVATYON (IST) interim analysis relapsed OC (2q´17) .
* Aplidin® CHMP recommendation in multiple myeloma (2H 2017) .
* Lurbinectedin Phase III data in platinum-resistant ovarian cancer (2H 2017) .
* Aplidin® OS data Phase III for multiple myeloma expected 2H17 .
* Lurbinectedin potential start of Phase III BRCA .
* Lurbinectedin expected publication of Phase II data as a single agent in SCLC .
La Presentación consta de 27 Paginas ... Picar en el Titular del Post .